Scholarlink

Purpose <p>Metabolic associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease, and non-invasive fibrosis staging still represents a challenge. Our main objective was to estimate the degree of liver fibrosis in these patients using T1 mapping and the extracellular volume (ECV) by MRI in comparison with liver stiffness assessed by MR elastography (MRE).</p> Methods <p>In a single-center cross-sectional study, patients with MASLD were prospectively enrolled and underwent MRI with liver T1 mapping and ECV calculations. Groups with and without significant liver fibrosis assessed by MRE were compared with the Mann–Whitney test, chi-square test, and Fisher's exact test. Correlation analysis was conducted using Spearman’s test, and a receiver operating characteristic (ROC) curve was generated to assess the ability of ECV to differentiate between groups.</p> Results <p>This study evaluated 54 patients, 37% were men, with a mean age of 58.0 ± 12.0&#xa0;years. Mild liver fibrosis (F0–F1) was present in 38 patients, and significant fibrosis (F2–F4) was detected in 16 patients. Patients with significant fibrosis presented higher native T1 (954 ± 126 vs. 820 ± 123;<i> p</i> &lt; 0.001) and ECV (37.9% vs. 29.1%; <i>p</i> &lt; 0.001) values than those with no/mild fibrosis. Liver stiffness was correlated with native T1 (r = 0.512, <i>p</i> &lt; 0.001) and ECV (r = 0.443, <i>p</i> &lt; 0.001). The native liver T1 and ECV differentiated patients with and without significant liver fibrosis on MRE (AUC = 0.85 and 0.84, respectively).</p> Conclusion <p>Native T1 and ECV show potential as an alternative method for the non-invasive staging of fibrosis in patients with MASLD, although further validation in larger cohorts is needed.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

MRI-derived extracellular volume to assess liver fibrosis in patients with metabolic-associated steatotic liver disease

  • 期刊论文

  • 发表日期：

    2025年4月17日

查看全文
  • Flavia Vernin de Oliveira Terzi,
  • Daniella Braz Parente,
  • Gabriel Cordeiro Camargo,
  • Ana Maria Pittella,
  • Gilberto Silva-Junior,
  • Gabrielle Gonçalves de Novaes,
  • Jaime Araújo Oliveira Neto,
  • Julia Machado Barroso,
  • Martha Valéria Tavares Pinheiro,
  • Adriana Soares Xavier-de-Brito,
  • Renée Sarmento de Oliveira,
  • Rosana Souza Rodrigues,
  • Ronir Raggio Luiz,
  • Andréa Silvestre-Sousa,
  • Renata Mello Perez,
  • Renata Junqueira Moll-Bernardes

摘要

Purpose

Metabolic associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease, and non-invasive fibrosis staging still represents a challenge. Our main objective was to estimate the degree of liver fibrosis in these patients using T1 mapping and the extracellular volume (ECV) by MRI in comparison with liver stiffness assessed by MR elastography (MRE).

Methods

In a single-center cross-sectional study, patients with MASLD were prospectively enrolled and underwent MRI with liver T1 mapping and ECV calculations. Groups with and without significant liver fibrosis assessed by MRE were compared with the Mann–Whitney test, chi-square test, and Fisher's exact test. Correlation analysis was conducted using Spearman’s test, and a receiver operating characteristic (ROC) curve was generated to assess the ability of ECV to differentiate between groups.

Results

This study evaluated 54 patients, 37% were men, with a mean age of 58.0 ± 12.0 years. Mild liver fibrosis (F0–F1) was present in 38 patients, and significant fibrosis (F2–F4) was detected in 16 patients. Patients with significant fibrosis presented higher native T1 (954 ± 126 vs. 820 ± 123; p < 0.001) and ECV (37.9% vs. 29.1%; p < 0.001) values than those with no/mild fibrosis. Liver stiffness was correlated with native T1 (r = 0.512, p < 0.001) and ECV (r = 0.443, p < 0.001). The native liver T1 and ECV differentiated patients with and without significant liver fibrosis on MRE (AUC = 0.85 and 0.84, respectively).

Conclusion

Native T1 and ECV show potential as an alternative method for the non-invasive staging of fibrosis in patients with MASLD, although further validation in larger cohorts is needed.

Graphical abstract